Strong VC-trio Invest in PharmaSurgics Wound Healing Product

Gothenburg 2008-05-26

PharmaSurgics AB has received SEK 17 million to complete the preclinical development of their candidate drug (PXL01). The primary indication for PXL01 is the prevention of post-surgical adhesions and the clinical documentation will start in Q1 2009. The investment round led by Karolinska Development (KD) also included Östersjöstiftelsen and Midroc New Technology.